US11413333B2 - Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock - Google Patents

Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock Download PDF

Info

Publication number
US11413333B2
US11413333B2 US15/889,393 US201815889393A US11413333B2 US 11413333 B2 US11413333 B2 US 11413333B2 US 201815889393 A US201815889393 A US 201815889393A US 11413333 B2 US11413333 B2 US 11413333B2
Authority
US
United States
Prior art keywords
sirt1
sepsis
septic shock
interferon beta
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/889,393
Other versions
US20180161398A1 (en
Inventor
Myung Kwan Han
Chae Hwa Yoo
Eun Kyung Song
Seung Ok Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STEMDR Inc
STEMDR Inc
Original Assignee
STEMDR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STEMDR Inc filed Critical STEMDR Inc
Priority to US15/889,393 priority Critical patent/US11413333B2/en
Assigned to STEMDR INC. reassignment STEMDR INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HAN, MYUNG KWAN, LEE, SEUNG OK, SONG, EUN KYUNG, YOO, CHAE HWA
Publication of US20180161398A1 publication Critical patent/US20180161398A1/en
Application granted granted Critical
Publication of US11413333B2 publication Critical patent/US11413333B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating a sepsis or septic shock.
  • SIRT1 inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating a sepsis or septic shock.
  • SIRS systemic inflammation or a systemic inflammatory response system
  • a serious SIRS causes serious fever, hypotoxemia, trachypnea, tachycardia, endothelium inflammation, myocardial dysfunction, mental disorder, blood vessel collapse, and eventually a multiple organ failure syndrome (MODS) which accompanies an organ injury, e.g., an acute respiratory distress syndrome, coagulation disorder, heart failure, renal failure, shock and/or coma.
  • MODS multiple organ failure syndrome
  • a sepsis is defined as a situation in which an infection has been confirmed or is doubted along with a systemic inflammatory response.
  • a sever sepsis is defined as a case in which a sepsis is accompanied by an organ dysfunction (low blood pressure, hypoxia, oliguria, metabolic acidosis, thrombocytopenia, consciousness disorder).
  • a septic shock is defined as a case in which blood pressure is not normalized even if infusion therapy is used or medicine for enhancing blood pressure is used. The sepsis may progress to a severe sepsis and finally a clinical step of a septic shock.
  • the clinical sepsis is defined in a broad sense as a state in which the invasion by the microorganism agent is related with the clinical symptoms of the infection.
  • the clinical symptoms of the sepsis are (1) Body temperature >38° C. or ⁇ 36° C.; (2) Heart rate >90 times per minute; (3) Respiratory rate >20 times per minute or PaCO 2 ⁇ 32 mmHg; (4) The number of white corpuscles >12000/cu mm, ⁇ 4,000/cu mm or >10% immature (band) form; (5) organ dysfunction or high blood pressure, but the present invention is not limited to these examples.
  • the macrophage of the infection region is activated so as to secrete TNF- ⁇ and IL-1, thereby the amount of discharge of the plasma protein into the organs increases, the movement of phagocytes and lymphocytes to the organs increases, and the attachment of the blood platelets on the walls of the blood vessels increases. In this way, the local blood vessels are closed, and the pathogenic organisms are concentrated on the infected region. Particularly, in sepsis, the systemic infection occurs, and the serious blood vessel closure induced by TNF- ⁇ is accompanied. Further, the systemic discharge of TNF- ⁇ causes the loss of the volume of the blood plasma due to the blood vessel enlargement and the increase of the permeability of the blood vessel, thereby causing shock.
  • TNF- ⁇ further stimulates blood coagulation, thereby causing generation of blood clots and mass consumption of blood coagulation protein in small blood vessels. Since the blood coagulation ability of a patient is lost, important organs such as kidney, liver, heart, and lung are damaged by the dysfunction of the normal vessels. It has been reported that the mortalities of severe sepsis and septic shock reach 25 to 30% and 40 to 70%, respectively.
  • the pathogenic organism is E. coli , but gram negative bacteria such as Klebsiella - Enterobacter - Serratia group and Pseudomonas may also cause such a state. Gram-positive microorganisms such as Staphylococcus , systemic viruses and Fungus may also cause sepsis.
  • Urogenital vessel, gastrointestinal vessel and respiratory tract are the most commonly infected regions which cause sepsis.
  • other sepsis-related infection regions are a cut or burn region, a pelvic infection region and a catheter infection region within a vein, etc.
  • Sepsis mostly frequently occurs in a hospitalized patient suffering from a basal disease or symptom sensitive to the invasion of the hematocele, or a burn, wound or surgical patient.
  • Factors of making a person sensitive to the invasion of the hematocele are a weakened immune system, for example, an immune system of an infant or an elderly person, and a symptom or disease which increases a local sensitivity to infection, for example, a weakened circulation, diabetes, uremia and AIDS.
  • a subject having a tendency of a weakened immune response which may occur due to the existence of various allelic genes of IL-1 gene also has a greater possibility of an outbreak of sepsis (U.S. Pat. No. 6,251,598).
  • sepsis is generated as a result of complicated reciprocal action between bacteria causing infection and the immune, inflammation and coagulation system of the host. Both the response level of the host and the features of the bacteria causing infection significantly affect the convalescence of sepsis. Organ failure observed in sepsis occurs when the response to the bacteria causing the infection of the host is inappropriate, and if the response is excessively increased, the organ of the host itself may be damaged.
  • SIRT1 sirtuin 1
  • NAD+ Ageing Res, Vol. 1, pages 313-326, (2002)
  • SIRT1 cuts the acetyl group attached on the transcription factor such as Nuclear factor-kB and p53 (Cancer Res, Vol. 64, pages 7513-7525, (2004); Cell, Vol. 107, pages 149-159, (2001); Trends Endocrinol Metab, Vol. 17, pages 186-191, (2006)).
  • SIRT1 participates in reconfiguration of chromatin related with the inhibition of gene expression, DNA damage response, life extension related with restricted diet, etc. (Chen et al., Science 310, 1641, 2005). That is, SIRT1 reconfigures chromatin through histone deacetylation as in Sir2 of the yeast, inhibits expression of gene, and induces deacetylation of various transcription factors related with cell growth, stress reaction and internal secretion regulation, etc. as well as histone protein. Further, according to a recent study, there has been a report of a technology which applies the SIRT1 to diabetes, obesity, nervous degenerative diseases or aging related diseases, etc. by increasing the deacetylation of the SIRT1.
  • the SIRT1 may be applicable to various diseases by increasing the deacetylation activity, but there is no study on pharmacological effects for preventing or treating sepsis or septic shock. Hence, there is a need for a new treatment for preventing or treating sepsis or septic shock.
  • the inventors of the present invention have been developing a new treatment of sepsis or septic shock, and have found that an SIRT1 expression inducer may significantly reduce the mortality by sepsis by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines.
  • an object of the present invention devised to solve the problem lies in providing a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
  • SIRT1 inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
  • the present invention provides a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
  • SIRT1 inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
  • the present invention provides a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or improving sepsis or septic shock.
  • SIRT1 inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or improving sepsis or septic shock.
  • an SIRT1 expression inducer may significantly reduce the mortality by sepsis by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines, and thus may be utilized in preventing or treating sepsis or septic shock.
  • FIG. 1 shows the result of an analysis of SIRT protein expression by western blot after (A) treatment of LPS and interferon beta and (B) treatment of IFN- ⁇ blocking antibody (a-INF ⁇ ) and LPS to a macrophage originated from the marrow of a mouse.
  • FIG. 2 shows the result of an analysis of the amount of pro-inflammatory cytokines and anti-inflammatory cytokines secreted after inducing overexpression of SIRT1 using adenovirus-SIRT1 and interferon beta to the macrophage originated from the mouse marrow and processing LPS ((*, P ⁇ 0.05; **, P ⁇ 0.01 (Student test)).
  • FIG. 3 shows the survival rate of the mouse after injecting LPS after pre-treatment of adenovirus-SIRT1 or interferon beta to the mouse.
  • FIG. 4 shows the survival rate of the mouse after processing LPS after injecting Adenovirus-Dominant-negative SIRT1 and interferon beta to the mouse.
  • FIG. 5 shows the survival rate of the mouse after causing sepsis by cecal ligation and Puncture (CLP) operation after treatment of adenovirus-SIRT1 or interferon beta to the mouse.
  • CLP cecal ligation and Puncture
  • the present invention provides a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
  • SIRT1 inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
  • the composition includes a pharmaceutical composition and food composition.
  • an SIRT1 expression inducer may significantly reduce the mortality by sepsis by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines, and thus may be utilized in preventing or treating sepsis or septic shock.
  • the SIRT expression inducing material may include at least one selected from a group composed of an interferon beta, cyclic guanosine monophosphate (cGMP), adiponectin, pyruvate, and 2-deoxyglucose, but the present invention is not limited thereto.
  • cGMP cyclic guanosine monophosphate
  • pyruvate pyruvate
  • 2-deoxyglucose 2-deoxyglucose
  • the interferon beta may include one of two isoforms, i.e., interferon beta 1a (IFN- ⁇ 1a) and interferon beta 1b (IFN- ⁇ 1b).
  • Interferon beta 1a is produced from Chinese hamster ovary (CHO) containing human interferon beta genes, is composed of 166 amino acid residues, and is a glycosylated protein having a size of 25 kD.
  • Interferon beta 1b is a protein composed of 165 amino acid residues produced from E. coli , does not have sugar, and does not have the amino acid number 1 methionine residue. Further, the number 17 cysteine residue has been substituted by serine. It is known that interferon beta 1a and interferon beta 1b may be used to treat multiple sclerosis, but it is not known that they are used to prevent or treat sepsis or septic shock.
  • the prevention or treatment of sepsis or septic shock means reducing, improving or removing clinical symptoms related with sepsis and the state related to the multi-organ failure syndrome, for example, fever, hypotoxemia, trachypnea, tachycardia, endothelium inflammation, myocardial dysfunction, mental disorder, blood vessel collapse, and eventually an organ injury, e.g., an acute respiratory distress syndrome, coagulation disorder, heart failure, renal failure, shock and/or coma.
  • an organ injury e.g., an acute respiratory distress syndrome, coagulation disorder, heart failure, renal failure, shock and/or coma.
  • composition of the present invention may contain one of known valid elements having the effects of preventing or treating sepsis or septic shock along with SIRT1 expression inducing materials.
  • the pharmaceutical composition of the present invention may include at least one of pharmaceutically allowable carriers for injection in addition to the above disclosed valid elements.
  • a carrier, an excipient, and a diluent are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, propyl hydroxybenzoate, talc, magnesium stearate, and mineral.
  • the pharmaceutical composition of the present invention may be prepared using a generally used filler, an extender, a binder, a wetting agent, a disintegrant, a diluent such as a surfactant, or an excipient.
  • Solid content for oral dosage includes a tablet, pill, powder, granule, capsule, etc., and the solid content is prepared mixing the above valid element with at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. Further, a lubricant such as magnesium stearate and talc may also be used in addition to a simple excipient.
  • excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc.
  • a lubricant such as magnesium stearate and talc may also be used in addition to a simple excipient.
  • Liquid substances for oral dosage may mean a suspension, liquid, oil, syrup, etc., and may include various excipients such as a wetting agent, a sweetener, an aromatic, and a preservative.
  • Substances for parenteral dosage include sterilized aqueous solution, suspension, non-aqueous solvent, oil, lyophilization materials, and suppository.
  • Plant oil such as propylene glycol, polyethylene glycol, and olive oil, and injectable esters such as ethylolate may be used as a suspended and non-aqueous solvent such as WITEPSOL®, macrogol, twin 61, cacao butter, Laurin, and glycerinated gelatin, etc.
  • compositions of the present invention may be injected in various ways according to a purposed method.
  • the composition may be injected by oral dosage, rectum, vein, muscle, hypodermic injection, intradural injection within the womb, or cerebrovascular injection.
  • the valid amount of injection of the pharmaceutical composition of the present invention may be different depending on the patient's state, weight, level of disease, type of composition, injection path, and period, but may also be appropriately selected by those skilled in the art.
  • the daily amount of injection of the SIRT1 expression inducing material is preferably between 5000 and 50000 IU/kg, the amount may be injected once a day or the amount may be divided into several parts to be injected several times a day, but the injection method of the present invention is not limited to this example.
  • composition of the present invention may be used along with an anti-inflammatory agent, antipyretic anodyne, blood coagulation inhibitor, antibiotic, bactericide, anti-allergy agent, etc.
  • the food composition of the present invention may additionally include a carrier allowable as food.
  • a carrier allowable as food.
  • a natural carbohydrate are a monosaccharide such as glucose and fructose, a disaccharide such as maltose and sucrose, a polysaccharide such as dextrin and a cyclodextrin, and a sugar alcohol such as xylitol, sorbitol, and erythritol, etc.
  • the flavoring agent are natural flavoring agents such as thaumatin, stevia extracts, and glycyrrhizin, and synthetic flavoring agents such as saccharin and aspartame.
  • the food composition of the present invention may contain various medicines for promoting nutrition, vitamins, minerals, synthetic flavoring agents, natural flavoring agents, coloring agents, enhancers, pectic acids, alginic acids, salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation reagents used in soda, etc.
  • the food composition may be provided as various foods, candy, chocolate, gum, tea, vitamin complex, various health supplements, etc., and may be provided in the form of powder, granules, pills, capsules or drinks.
  • the valid amount of the SIRT1 expression inducing material contained in the food composition may be set according to the valid amount of the pharmaceutical composition, but when the food composition is taken in for a long period for the purpose of health or hygiene, or for the purpose of health adjustment, the valid amount may be less than the above amount.
  • Femur and tibia marrow cells of C57BL/6 mouse have been differentiated in culture solution containing M-CSF (10 ng/ml), and then have been used as mouse macrophage.
  • LPS (0, 100, 500, 1000 ng/ml) and interferon beta (0, 100, 200, 500 units/ml) have been injected to the macrophage by concentrations, and the SIRT1 expression amount has been compared by western blot. Further, the SIRT1 protein expression amount when LPS has been injected along with IFN- ⁇ blocking antibody has been measured.
  • FIG. 1 The result is shown in FIG. 1 .
  • the SIRT protein expression has increased most, and when 500 ng/ml and 1000 ng/ml of LPS has been used, the SIRT1 protein expression has rather decreased. Further, when interferon beta has been used by concentrations, the SIRT1 expression has most significantly increased when 100 units/ml has been used.
  • SIRT1 expression increased by LPS decreased again by injecting IFN- ⁇ blocking antibody together.
  • SIRT1 the secretion of the SIRT1, which has been increased by LPS, is performed through interferon beta, and through which interferon beta induces the expression of SIRT1 (B).
  • LPS 100 ng/ml After infecting the macrophage with the adenovirus-SIRT1 by 10,000 MOI (multiplicity of infection), LPS 100 ng/ml has been injected for 24 hours. Further, LPS 100 ng/ml has been used along with interferon beta 100 units/ml for 24 hours, and then the amount of secretion of pro-inflammatory and anti-inflammatory cytokines of the cell culture medium has been measured by Elisa. The experiment has been performed three times, and the result has been expressed by the average ⁇ standard deviation.
  • Adenovirus-LacZ which is a control gene delivery system
  • adenovirus-SIRT1 which is the SIRT1 gene delivery system
  • interferon beta 1000 units or the same amount of salt solution per 20 g of the mouse weight is injected into the mouse tail vein, and LPS 15 ⁇ 20 mg/kg has been injected after 30 minutes. Then the survival rate of the mouse has been observed for 10 days.
  • the survival rate of the mouse after 10 days is 66%, and thus the survival rate has been significantly higher than the 20% survival rate of the control group, the mouse, to which the adenovirus-LacZ has been injected.
  • the survival rate of the mouse, into which the LPS has been injected after the injection of the interferon beta was 70%, which was significantly higher than the survival rate of 30% of the control group, the mouse, into which the salt solution has been injected.
  • the result shows a significant difference even by the Kaplan-Meier survival statistical analysis (p ⁇ 0.05).
  • the interferon beta which is a substance that induces the SIRT1 expression, significantly reduces the mortality of the mouse by the LPS treatment by inhibiting the excessive inflammatory response by the LPS.
  • Adenovirus-Dominant-negative SIRT1 which is the gene delivery system for blocking the function of the intrinsic SIRT1 (Adenovirus for inducing mutant protein that has changed histidine no. 355 into tyrosine), is injected into the mouse tail vein by 3 ⁇ 10 8 pfu, and after 48 hours, interferon beta 1000 units per 20 g of the mouse weight is injected into the mouse tail vein. After 30 minutes, LPS 15 ⁇ 20 mg/kg is injected, and the survival rate of the mouse is observed for 10 days.
  • Adenovirus-LacZ or adenovirus-SIRT1 has been injected into the mouse tail vein by 3 ⁇ 10 8 pfu.
  • the anesthetic is injected into the abdominal cavity, and the sepsis has been caused through CLP. That is, after the center of the abdomen of the mouse is cut, the appendix is exposed to the outside so that the end of the ileocecal valve is ligated by the silk suture, two holes are made using a needle, and then a certain amount of fecal materials are discharged.
  • the appendix as well as fecal materials were inserted again into the abdomen, then the abdomen was stitched, and then a physiological salt solution was injected through a hypodermic injection.
  • interferon beta 1000 units or the same amount of salt solution per 20 g of the mouse weight have been injected into the mouse tail vein.
  • the sepsis is induced to the mouse into which the adenovirus-SIRT1 has been injected in advance, and the survival rate of the mouse after 10 days was 60%. This is a significantly high survival rate of 0% of the control group, the mouse into which the adenovirus-LacZ has been injected in advance.
  • the survival rate was 76%, but in the case of the control group, the mouse into which the salt solution has been injected, the survival rate was 0%.
  • the result shows a significant difference even by Kaplan-Meier survival statistical analysis (p ⁇ 0.05).
  • the interferon beta which induces the expression of SIRT1 significantly reduces the mortality of the mouse due to the sepsis, and thus may be utilized in preventing or treating the sepsis or septic shock.
  • the above materials are mixed and are then filled in an airtight container so as to make powder.
  • pills are manufactured according to a general pill manufacturing method.
  • capsules are prepared in gelatin capsules according to a general capsule manufacturing method.
  • Spice for cooking for health improvement has been made as 20 to 95 weights of SIRT1 expression inducing materials.
  • SIRT1 expression inducing materials 0.5 to 5.0 weight % are added to wheat flour, and then bread, cake, cookies, crackers and noodles are made using the mixture so as to prepare food for health improvement.
  • SIRT1 expression inducing materials 0.1 to 5.0 weight % are added to soups and gravies so as to prepare meat processed food, soups of noodles, and gravies for health improvement.
  • SIRT1 expression inducing materials 5 to 10 weight % is added to milk, and various diary products such as butter and ice cream are made using the milk.
  • SIRT expression inducing materials 10 to 15% of SIRT expression inducing materials, 5 to 10% of sugar, 0.05 to 0.3% of citric acid, 0.005 to 0.02% of caramel, 0.1 to 1% of vitamin C and 70 to 80% of refined water are mixed to make syrup.
  • the syrup is sterilized for 20 to 180 seconds at 85 ⁇ 98° C., and the syrup is mixed with the cooling water at the ratio of 1:4, then 0.5 to 0.82% of carbonic acid gas is injected so as to prepare soda containing SIRT1 expression inducing materials.
  • SIRT1 expression inducing materials solid content 2.5%, 97.16%
  • jujube extract 65 brix, 2.67%
  • fruit and vegetable extract solid content 70%, 0.12%
  • vitamin C 0.02%
  • calcium pantothenate 0.02%
  • licorice extract solid content 65%, 0.01%
  • SIRT1 expression inducing materials 0.5 g is added to 1.00 ml of tomato or carrot juice so as to make a vegetable juice for health improvement.
  • SIRT1 expression inducing materials 0.1 g is added to 1,000 ml of apple or grape juice so as to make a fruit juice for health improvement.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock. The inducer of SIRT1 expression can remarkably reduce the mortality caused by sepsis or septic shock by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines. Therefore, the inducer of SIRT1 expression is useful for preventing or treating sepsis or septic shock.

Description

CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation application of U.S. Ser. No. 13/818,847, filed Feb. 25, 2013, which is a national stage application under 35 U.S.C. 371 of PCT Application No. PCT/KR2012/01225, having an international filing date of Feb. 17, 2012, which designated the United States, which PCT application claim claimed the benefit of Korean Application No. 10-2012-0016524, filed Feb. 17, 2012 and Korean Application No. 10-2011-0014474, filed Feb. 18, 2011, the entire disclosures of each is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating a sepsis or septic shock.
BACKGROUND ART
Bacterial infections and other strong stimuli may initiate an immune reaction which may cause a systemic inflammation or a systemic inflammatory response system (SIRS). A serious SIRS causes serious fever, hypotoxemia, trachypnea, tachycardia, endothelium inflammation, myocardial dysfunction, mental disorder, blood vessel collapse, and eventually a multiple organ failure syndrome (MODS) which accompanies an organ injury, e.g., an acute respiratory distress syndrome, coagulation disorder, heart failure, renal failure, shock and/or coma.
A sepsis is defined as a situation in which an infection has been confirmed or is doubted along with a systemic inflammatory response. A sever sepsis is defined as a case in which a sepsis is accompanied by an organ dysfunction (low blood pressure, hypoxia, oliguria, metabolic acidosis, thrombocytopenia, consciousness disorder). A septic shock is defined as a case in which blood pressure is not normalized even if infusion therapy is used or medicine for enhancing blood pressure is used. The sepsis may progress to a severe sepsis and finally a clinical step of a septic shock. The clinical sepsis is defined in a broad sense as a state in which the invasion by the microorganism agent is related with the clinical symptoms of the infection. The clinical symptoms of the sepsis are (1) Body temperature >38° C. or <36° C.; (2) Heart rate >90 times per minute; (3) Respiratory rate >20 times per minute or PaCO2<32 mmHg; (4) The number of white corpuscles >12000/cu mm, <4,000/cu mm or >10% immature (band) form; (5) organ dysfunction or high blood pressure, but the present invention is not limited to these examples.
If an infection occurs, the macrophage of the infection region is activated so as to secrete TNF-α and IL-1, thereby the amount of discharge of the plasma protein into the organs increases, the movement of phagocytes and lymphocytes to the organs increases, and the attachment of the blood platelets on the walls of the blood vessels increases. In this way, the local blood vessels are closed, and the pathogenic organisms are concentrated on the infected region. Particularly, in sepsis, the systemic infection occurs, and the serious blood vessel closure induced by TNF-α is accompanied. Further, the systemic discharge of TNF-α causes the loss of the volume of the blood plasma due to the blood vessel enlargement and the increase of the permeability of the blood vessel, thereby causing shock. In septic shock, TNF-α further stimulates blood coagulation, thereby causing generation of blood clots and mass consumption of blood coagulation protein in small blood vessels. Since the blood coagulation ability of a patient is lost, important organs such as kidney, liver, heart, and lung are damaged by the dysfunction of the normal vessels. It has been reported that the mortalities of severe sepsis and septic shock reach 25 to 30% and 40 to 70%, respectively.
In many cases of sepsis, the pathogenic organism is E. coli, but gram negative bacteria such as Klebsiella-Enterobacter-Serratia group and Pseudomonas may also cause such a state. Gram-positive microorganisms such as Staphylococcus, systemic viruses and Fungus may also cause sepsis.
Urogenital vessel, gastrointestinal vessel and respiratory tract are the most commonly infected regions which cause sepsis. In addition, other sepsis-related infection regions are a cut or burn region, a pelvic infection region and a catheter infection region within a vein, etc.
Sepsis mostly frequently occurs in a hospitalized patient suffering from a basal disease or symptom sensitive to the invasion of the hematocele, or a burn, wound or surgical patient. Factors of making a person sensitive to the invasion of the hematocele are a weakened immune system, for example, an immune system of an infant or an elderly person, and a symptom or disease which increases a local sensitivity to infection, for example, a weakened circulation, diabetes, uremia and AIDS. Finally, a subject having a tendency of a weakened immune response which may occur due to the existence of various allelic genes of IL-1 gene also has a greater possibility of an outbreak of sepsis (U.S. Pat. No. 6,251,598).
It is understood that sepsis is generated as a result of complicated reciprocal action between bacteria causing infection and the immune, inflammation and coagulation system of the host. Both the response level of the host and the features of the bacteria causing infection significantly affect the convalescence of sepsis. Organ failure observed in sepsis occurs when the response to the bacteria causing the infection of the host is inappropriate, and if the response is excessively increased, the organ of the host itself may be damaged. Based on this concept, antagonists to TNF-α, IL-1β, IL-6, which are proinflammatory cytokines that perform a leading role in the inflammation response to the host, has been used in an attempt to cure sepsis, but most of the attempts have failed, and injection of activated protein C and treatment of glucocorticoid are now being used in an attempt to cure sepsis, but many limits are being indicated. Hence, there is a need for a new treatment for preventing or treating sepsis and septic shock.
SIRT1 (silent mating type information regulation 2 homolog; sirtuin 1) is known as an enzyme for regulating the function of the protein by deacetylating the lysine residue of various proteins, which depends on NAD+ (Ageing Res, Vol. 1, pages 313-326, (2002)), and is most similar to Sir2 of the yeast having (NAD+)-dependent class III histone deacetyl activity. In particularly, SIRT1 cuts the acetyl group attached on the transcription factor such as Nuclear factor-kB and p53 (Cancer Res, Vol. 64, pages 7513-7525, (2004); Cell, Vol. 107, pages 149-159, (2001); Trends Endocrinol Metab, Vol. 17, pages 186-191, (2006)). Further, SIRT1 participates in reconfiguration of chromatin related with the inhibition of gene expression, DNA damage response, life extension related with restricted diet, etc. (Chen et al., Science 310, 1641, 2005). That is, SIRT1 reconfigures chromatin through histone deacetylation as in Sir2 of the yeast, inhibits expression of gene, and induces deacetylation of various transcription factors related with cell growth, stress reaction and internal secretion regulation, etc. as well as histone protein. Further, according to a recent study, there has been a report of a technology which applies the SIRT1 to diabetes, obesity, nervous degenerative diseases or aging related diseases, etc. by increasing the deacetylation of the SIRT1.
Likewise, there is a report on pharmacological effects that the SIRT1 may be applicable to various diseases by increasing the deacetylation activity, but there is no study on pharmacological effects for preventing or treating sepsis or septic shock. Hence, there is a need for a new treatment for preventing or treating sepsis or septic shock.
DISCLOSURE Technical Problem
The inventors of the present invention have been developing a new treatment of sepsis or septic shock, and have found that an SIRT1 expression inducer may significantly reduce the mortality by sepsis by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines.
Hence, an object of the present invention devised to solve the problem lies in providing a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
Technical Solution
The present invention provides a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
Further, the present invention provides a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or improving sepsis or septic shock.
Advantageous Effects
According to the present invention, an SIRT1 expression inducer may significantly reduce the mortality by sepsis by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines, and thus may be utilized in preventing or treating sepsis or septic shock.
DESCRIPTION OF DRAWINGS
FIG. 1 shows the result of an analysis of SIRT protein expression by western blot after (A) treatment of LPS and interferon beta and (B) treatment of IFN-β blocking antibody (a-INF β) and LPS to a macrophage originated from the marrow of a mouse.
FIG. 2 shows the result of an analysis of the amount of pro-inflammatory cytokines and anti-inflammatory cytokines secreted after inducing overexpression of SIRT1 using adenovirus-SIRT1 and interferon beta to the macrophage originated from the mouse marrow and processing LPS ((*, P<0.05; **, P<0.01 (Student test)).
FIG. 3 shows the survival rate of the mouse after injecting LPS after pre-treatment of adenovirus-SIRT1 or interferon beta to the mouse.
FIG. 4 shows the survival rate of the mouse after processing LPS after injecting Adenovirus-Dominant-negative SIRT1 and interferon beta to the mouse.
FIG. 5 shows the survival rate of the mouse after causing sepsis by cecal ligation and Puncture (CLP) operation after treatment of adenovirus-SIRT1 or interferon beta to the mouse.
 BEST MODE
The present invention provides a composition containing an inducer of SIRT1 (silent mating type information regulation 2 homolog) expression for preventing or treating sepsis or septic shock.
The composition includes a pharmaceutical composition and food composition.
Hereinafter, the present invention will be described in detail.
According to the present invention, an SIRT1 expression inducer may significantly reduce the mortality by sepsis by reducing pro-inflammatory cytokines and increasing anti-inflammatory cytokines, and thus may be utilized in preventing or treating sepsis or septic shock.
The SIRT expression inducing material may include at least one selected from a group composed of an interferon beta, cyclic guanosine monophosphate (cGMP), adiponectin, pyruvate, and 2-deoxyglucose, but the present invention is not limited thereto.
The interferon beta may include one of two isoforms, i.e., interferon beta 1a (IFN-β1a) and interferon beta 1b (IFN-β1b). Interferon beta 1a is produced from Chinese hamster ovary (CHO) containing human interferon beta genes, is composed of 166 amino acid residues, and is a glycosylated protein having a size of 25 kD. Interferon beta 1b is a protein composed of 165 amino acid residues produced from E. coli, does not have sugar, and does not have the amino acid number 1 methionine residue. Further, the number 17 cysteine residue has been substituted by serine. It is known that interferon beta 1a and interferon beta 1b may be used to treat multiple sclerosis, but it is not known that they are used to prevent or treat sepsis or septic shock.
The prevention or treatment of sepsis or septic shock means reducing, improving or removing clinical symptoms related with sepsis and the state related to the multi-organ failure syndrome, for example, fever, hypotoxemia, trachypnea, tachycardia, endothelium inflammation, myocardial dysfunction, mental disorder, blood vessel collapse, and eventually an organ injury, e.g., an acute respiratory distress syndrome, coagulation disorder, heart failure, renal failure, shock and/or coma.
The composition of the present invention may contain one of known valid elements having the effects of preventing or treating sepsis or septic shock along with SIRT1 expression inducing materials.
The pharmaceutical composition of the present invention may include at least one of pharmaceutically allowable carriers for injection in addition to the above disclosed valid elements. Some examples of a carrier, an excipient, and a diluent are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, propyl hydroxybenzoate, talc, magnesium stearate, and mineral. The pharmaceutical composition of the present invention may be prepared using a generally used filler, an extender, a binder, a wetting agent, a disintegrant, a diluent such as a surfactant, or an excipient.
Solid content for oral dosage includes a tablet, pill, powder, granule, capsule, etc., and the solid content is prepared mixing the above valid element with at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin, etc. Further, a lubricant such as magnesium stearate and talc may also be used in addition to a simple excipient.
Liquid substances for oral dosage may mean a suspension, liquid, oil, syrup, etc., and may include various excipients such as a wetting agent, a sweetener, an aromatic, and a preservative.
Substances for parenteral dosage include sterilized aqueous solution, suspension, non-aqueous solvent, oil, lyophilization materials, and suppository. Plant oil such as propylene glycol, polyethylene glycol, and olive oil, and injectable esters such as ethylolate may be used as a suspended and non-aqueous solvent such as WITEPSOL®, macrogol, twin 61, cacao butter, Laurin, and glycerinated gelatin, etc.
Pharmaceutical compositions of the present invention may be injected in various ways according to a purposed method. For example, the composition may be injected by oral dosage, rectum, vein, muscle, hypodermic injection, intradural injection within the womb, or cerebrovascular injection.
The valid amount of injection of the pharmaceutical composition of the present invention may be different depending on the patient's state, weight, level of disease, type of composition, injection path, and period, but may also be appropriately selected by those skilled in the art. The daily amount of injection of the SIRT1 expression inducing material is preferably between 5000 and 50000 IU/kg, the amount may be injected once a day or the amount may be divided into several parts to be injected several times a day, but the injection method of the present invention is not limited to this example.
Further, the pharmaceutical composition of the present invention may be used along with an anti-inflammatory agent, antipyretic anodyne, blood coagulation inhibitor, antibiotic, bactericide, anti-allergy agent, etc.
The food composition of the present invention may additionally include a carrier allowable as food. For example, when the food composition is a drink, there is no restriction in the liquid except the fact that SIRT1 expression inducing material should be contained as an essential element, and several flavoring agents or natural carbohydrate, etc. may be contained as in common drinks. At this time, some examples of a natural carbohydrate are a monosaccharide such as glucose and fructose, a disaccharide such as maltose and sucrose, a polysaccharide such as dextrin and a cyclodextrin, and a sugar alcohol such as xylitol, sorbitol, and erythritol, etc. Further, some examples of the flavoring agent are natural flavoring agents such as thaumatin, stevia extracts, and glycyrrhizin, and synthetic flavoring agents such as saccharin and aspartame.
In addition to the above drinks, the food composition of the present invention may contain various medicines for promoting nutrition, vitamins, minerals, synthetic flavoring agents, natural flavoring agents, coloring agents, enhancers, pectic acids, alginic acids, salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonation reagents used in soda, etc.
The food composition may be provided as various foods, candy, chocolate, gum, tea, vitamin complex, various health supplements, etc., and may be provided in the form of powder, granules, pills, capsules or drinks.
The valid amount of the SIRT1 expression inducing material contained in the food composition may be set according to the valid amount of the pharmaceutical composition, but when the food composition is taken in for a long period for the purpose of health or hygiene, or for the purpose of health adjustment, the valid amount may be less than the above amount.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
Hereinafter, exemplary embodiments of the present invention will be described in detail. However, the exemplary embodiments below merely illustrate the present invention, and the present invention is not limited to the embodiments.
Exemplary Embodiment 1: Measuring Amount of SIRT1 Expression after Treatment of LPS and Interferon to Macrophage Originated from Mouse Marrow
Femur and tibia marrow cells of C57BL/6 mouse have been differentiated in culture solution containing M-CSF (10 ng/ml), and then have been used as mouse macrophage. LPS (0, 100, 500, 1000 ng/ml) and interferon beta (0, 100, 200, 500 units/ml) have been injected to the macrophage by concentrations, and the SIRT1 expression amount has been compared by western blot. Further, the SIRT1 protein expression amount when LPS has been injected along with IFN-β blocking antibody has been measured.
The result is shown in FIG. 1.
As illustrated in FIG. 1, when LPS has been injected to the macrophage originated from the mouse marrow by 100 ng/ml, the SIRT protein expression has increased most, and when 500 ng/ml and 1000 ng/ml of LPS has been used, the SIRT1 protein expression has rather decreased. Further, when interferon beta has been used by concentrations, the SIRT1 expression has most significantly increased when 100 units/ml has been used.
Further, the SIRT1 expression increased by LPS decreased again by injecting IFN-β blocking antibody together. Hence, it can be known that the secretion of the SIRT1, which has been increased by LPS, is performed through interferon beta, and through which interferon beta induces the expression of SIRT1 (B).
Exemplary Embodiment 2: Influence of Adenovirus-SIRT1 and Interferon Beta on the Amount of Secretion of Pro-Inflammatory and Anti-Inflammatory Cytokines
After infecting the macrophage with the adenovirus-SIRT1 by 10,000 MOI (multiplicity of infection), LPS 100 ng/ml has been injected for 24 hours. Further, LPS 100 ng/ml has been used along with interferon beta 100 units/ml for 24 hours, and then the amount of secretion of pro-inflammatory and anti-inflammatory cytokines of the cell culture medium has been measured by Elisa. The experiment has been performed three times, and the result has been expressed by the average±standard deviation.
The result is shown in FIG. 2.
As shown in FIG. 2, with respect to the amount of the pro-inflammatory cytokines, which has been increased by the LPS treatment, IL-6 has been decreased by 40% and 54%, respectively, and TNF-α has been decreased by 22% and 29%, respectively, by the pre-treatment of adenovirus-SIRT1 and interferon beta. Further, it has been found that MCP-1, which is another pro-inflammatory cytokine, which is increased by the LPS treatment, has slightly decreased by the adenovirus-SIRT1 and interferon beta. In contrast, it has been found that the amount of the IL-10, which is the anti-inflammatory cytokine, has increased by 2.8 times and 4.7 times, respectively. Hence, it is understood that the treatment by the interferon beta, which is the cytokine that promotes the expression of SIRT1, may inhibit the excessive inflammatory response by the LPS.
Exemplary Embodiment 3: Analysis of Survival Rate of Mouse after Injecting LPS after Pre-Treatment of SIRT1 or Interferon Beta to Mouse
Adenovirus-LacZ, which is a control gene delivery system, and adenovirus-SIRT1, which is the SIRT1 gene delivery system, are injected into the mouse tail vein by 3×108 pfu (plaque forming unit), and LPS 15˜20 mg/kg after 48 hours. Then the survival rate of the mouse has been observed for 10 days.
Further, interferon beta 1000 units or the same amount of salt solution per 20 g of the mouse weight is injected into the mouse tail vein, and LPS 15˜20 mg/kg has been injected after 30 minutes. Then the survival rate of the mouse has been observed for 10 days.
The result is shown in FIG. 3.
As shown in FIG. 3, When the LPS is injected to the mouse which has been pre-injected with the adenovirus-SIRT1, the survival rate of the mouse after 10 days is 66%, and thus the survival rate has been significantly higher than the 20% survival rate of the control group, the mouse, to which the adenovirus-LacZ has been injected. Further, the survival rate of the mouse, into which the LPS has been injected after the injection of the interferon beta, was 70%, which was significantly higher than the survival rate of 30% of the control group, the mouse, into which the salt solution has been injected. The result shows a significant difference even by the Kaplan-Meier survival statistical analysis (p<0.05). Hence, the interferon beta, which is a substance that induces the SIRT1 expression, significantly reduces the mortality of the mouse by the LPS treatment by inhibiting the excessive inflammatory response by the LPS.
Exemplary Embodiment 4: Analysis of Survival Rate of Mouse at the Time of Treatment of Adenovirus-Dominant-Negative SIRT1
Adenovirus-Dominant-negative SIRT1, which is the gene delivery system for blocking the function of the intrinsic SIRT1, (Adenovirus for inducing mutant protein that has changed histidine no. 355 into tyrosine), is injected into the mouse tail vein by 3×108 pfu, and after 48 hours, interferon beta 1000 units per 20 g of the mouse weight is injected into the mouse tail vein. After 30 minutes, LPS 15˜20 mg/kg is injected, and the survival rate of the mouse is observed for 10 days.
The result is shown in FIG. 4.
As shown in FIG. 4, in the case in which Adenovirus-Dominant-negative SIRT1 is pre-injected for 48 hours, interferon beta is injected and then LPS is injected into the mouse, the survival rate of 50% has been observed after 10 days. This is a result similar to the survival rate of 50% of the control group, the mouse into which the salt solution has been injected, and through which the interferon beta, which is the material for inducing the SIRT1 expression, significantly reduces the mortality of the mouse by LPS.
Exemplary Embodiment 5: Analysis of Survival Rate According to SIRT1 and Interferon Beta Treatment in a Mouse Sepsis Model
In a mouse sepsis model, which is induced through cecal ligation and Puncture (CLP) surgery, the following experiment has been performed to check the survival rate change according to the injection of SIRT1 and interferon beta.
Adenovirus-LacZ or adenovirus-SIRT1 has been injected into the mouse tail vein by 3×108 pfu. After 24 hours, the anesthetic is injected into the abdominal cavity, and the sepsis has been caused through CLP. That is, after the center of the abdomen of the mouse is cut, the appendix is exposed to the outside so that the end of the ileocecal valve is ligated by the silk suture, two holes are made using a needle, and then a certain amount of fecal materials are discharged. The appendix as well as fecal materials were inserted again into the abdomen, then the abdomen was stitched, and then a physiological salt solution was injected through a hypodermic injection. After two hours of SLP operation, interferon beta 1000 units or the same amount of salt solution per 20 g of the mouse weight have been injected into the mouse tail vein.
The result is shown in FIG. 5.
As shown in FIG. 5, the sepsis is induced to the mouse into which the adenovirus-SIRT1 has been injected in advance, and the survival rate of the mouse after 10 days was 60%. This is a significantly high survival rate of 0% of the control group, the mouse into which the adenovirus-LacZ has been injected in advance.
Further, in the case of the experimental group in which interferon beta has been injected into the sepsis-induced mouse, the survival rate was 76%, but in the case of the control group, the mouse into which the salt solution has been injected, the survival rate was 0%. The result shows a significant difference even by Kaplan-Meier survival statistical analysis (p<0.05).
Hence, the interferon beta, which induces the expression of SIRT1, significantly reduces the mortality of the mouse due to the sepsis, and thus may be utilized in preventing or treating the sepsis or septic shock.
Substances for a composition of the present invention are illustrated below.
Substance Example 1: Pharmacological Substance
1. Preparation of Powder
2 g of SIRT1 expression inducing material
1 g of lactose
The above materials are mixed and are then filled in an airtight container so as to make powder.
2. Preparation of a Pill
100 mg of SIRT1 expression inducing material
100 mg of corn starch
100 mg lactose
2 mg of stearic acid magnesium
After mixing the above materials, pills are manufactured according to a general pill manufacturing method.
3. Preparation of Capsules
100 mg of SIRT1 expression inducing material
100 mg of corn starch
100 mg lactose
2 mg of stearic acid magnesium
After mixing the above materials, capsules are prepared in gelatin capsules according to a general capsule manufacturing method.
Substance Example 2: Preparation of Food
The foods containing SIRT1 expression inducing materials of the present invention have been made as follows.
1. Preparation of Spice for Cooking
Spice for cooking for health improvement has been made as 20 to 95 weights of SIRT1 expression inducing materials.
2. Preparation of Tomato Ketchup and Sauce
0.2 to 1.0 weights of SIRT1 expression inducing materials has been added to tomato ketchup or sauce so as to make tomato ketchup or sauce for health improvement.
3. Preparation of Wheat Flour Food
0.5 to 5.0 weight % of SIRT1 expression inducing materials are added to wheat flour, and then bread, cake, cookies, crackers and noodles are made using the mixture so as to prepare food for health improvement.
4. Preparation of Soup and Gravies
0.1 to 5.0 weight % of SIRT1 expression inducing materials are added to soups and gravies so as to prepare meat processed food, soups of noodles, and gravies for health improvement.
5. Preparation of Ground Beef
10 weight % of SIRT expression inducing materials is added to ground beef so as to prepare the ground beef for health improvement.
6. Preparation of Diary Products
5 to 10 weight % of SIRT1 expression inducing materials is added to milk, and various diary products such as butter and ice cream are made using the milk.
Substance Example 3: Preparation of Drinks
1. Preparation of Soda
10 to 15% of SIRT expression inducing materials, 5 to 10% of sugar, 0.05 to 0.3% of citric acid, 0.005 to 0.02% of caramel, 0.1 to 1% of vitamin C and 70 to 80% of refined water are mixed to make syrup. The syrup is sterilized for 20 to 180 seconds at 85˜98° C., and the syrup is mixed with the cooling water at the ratio of 1:4, then 0.5 to 0.82% of carbonic acid gas is injected so as to prepare soda containing SIRT1 expression inducing materials.
2. Preparation of Healthy Drinks
SIRT1 expression inducing materials (solid content 2.5%, 97.16%), jujube extract (65 brix, 2.67%), fruit and vegetable extract (solid content 70%, 0.12%), vitamin C (0.02%), calcium pantothenate (0.02%), licorice extract (solid content 65%, 0.01%) are mixed, then the mixture is sterilized for a few seconds, and then the mixture is packed in a small container such as a glass bottle and a plastic bottle so as to make a healthy drink.
3. Preparation of Vegetable Juice
0.5 g of SIRT1 expression inducing materials is added to 1.00 ml of tomato or carrot juice so as to make a vegetable juice for health improvement.
4. Preparation of Fruit Juice
0.1 g of SIRT1 expression inducing materials is added to 1,000 ml of apple or grape juice so as to make a fruit juice for health improvement.

Claims (7)

The invention claimed is:
1. A method for treating a sepsis or a septic shock in a patient, the method comprising: reducing a pro-inflammatory cytokine and increasing an anti-inflammatory cytokine in the patient by administering a therapeutically effective dose of interferon beta (IFN-β), wherein the dose of IFN-β induces expression of silent mating type information regulation 2 homolog (SIRT1) as an active ingredient to the patient, wherein the sepsis or the septic shock causes multi-organ failure syndrome.
2. The method of claim 1, wherein the interferon beta is interferon beta 1a or interferon beta 1b.
3. The method of claim 1, wherein the dose is in an amount between 5000 and 50000 IU/kg per day.
4. The method of claim 1, wherein the pro-inflammatory cytokine is interleukin 6 (IL-6).
5. The method of claim 1, wherein the pro-inflammatory cytokine is tumor necrosis factor alpha (TNF-α).
6. The method of claim 1, wherein the anti-inflammatory cytokine is interleukin 10 (IL-10).
7. The method of claim 1, further comprising reducing at least two different pro-inflammatory cytokines, including both IL-6 and (TNF-α).
US15/889,393 2011-02-18 2018-02-06 Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock Active 2033-10-18 US11413333B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/889,393 US11413333B2 (en) 2011-02-18 2018-02-06 Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR20110014474 2011-02-18
KR10-2011-0014474 2011-02-18
KR10-2012-0016524 2012-02-17
PCT/KR2012/001225 WO2012112007A2 (en) 2011-02-18 2012-02-17 Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
KR1020120016524A KR101451357B1 (en) 2011-02-18 2012-02-17 Composition for preventing or treating sepsis or septic shock comprising SIRT1 expression inducer
US201313818847A 2013-02-25 2013-02-25
US15/889,393 US11413333B2 (en) 2011-02-18 2018-02-06 Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2012/001225 Continuation WO2012112007A2 (en) 2011-02-18 2012-02-17 Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
US13/818,847 Continuation US9913880B2 (en) 2011-02-18 2012-02-17 Method of treating sepsis or septic shock

Publications (2)

Publication Number Publication Date
US20180161398A1 US20180161398A1 (en) 2018-06-14
US11413333B2 true US11413333B2 (en) 2022-08-16

Family

ID=46885896

Family Applications (2)

Application Number Title Priority Date Filing Date
US13/818,847 Active 2032-06-11 US9913880B2 (en) 2011-02-18 2012-02-17 Method of treating sepsis or septic shock
US15/889,393 Active 2033-10-18 US11413333B2 (en) 2011-02-18 2018-02-06 Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US13/818,847 Active 2032-06-11 US9913880B2 (en) 2011-02-18 2012-02-17 Method of treating sepsis or septic shock

Country Status (6)

Country Link
US (2) US9913880B2 (en)
EP (2) EP3395356B1 (en)
JP (3) JP2014506889A (en)
KR (1) KR101451357B1 (en)
CN (1) CN103228290A (en)
WO (1) WO2012112007A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260005230A (en) 2023-04-21 2026-01-09 이데미쓰 고산 가부시키가이샤 Compounds, materials for organic electroluminescent devices, organic electroluminescent devices and electronic devices

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3395356B1 (en) * 2011-02-18 2021-05-19 Stemdr Inc. Composition containing inducer of sirt1 expression for preventing or treating sepsis or septic shock
BR102014014999B1 (en) * 2014-06-18 2020-12-01 Hypera S.A. combination to protect the skin from damage caused by infrared radiation, composition and use of the combination
DE102020111571A1 (en) 2020-03-11 2021-09-16 Immatics US, Inc. WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND RELATED PROCEDURES
KR102594908B1 (en) * 2020-06-16 2023-10-30 전북대학교산학협력단 A composition for preventing, alleviating or treating a sepsis or septic shock
CN120549950B (en) * 2025-08-01 2025-11-18 南昌大学第一附属医院 Application of AdipoRon combined stevioside in preparation of sepsis related drugs

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03501382A (en) 1987-09-22 1991-03-28 カイロン　コーポレイション Use of recombinant colony stimulating factor-1
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
JP2002220343A (en) 2001-01-26 2002-08-09 Toray Ind Inc Life prolongation agent for diffuse lung disease
WO2002074301A1 (en) 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
WO2003055916A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Adiponectin fragments and conjugates
JP2004531546A (en) 2001-05-16 2004-10-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Use of an IL-18 inhibitor for the treatment or prevention of sepsis
JP2007535903A (en) 2003-05-13 2007-12-13 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Activity variants of IL-18 binding protein and their medical applications
JP2008540385A (en) 2005-05-06 2008-11-20 ラボラトワール セローノ ソシエテ アノニム Use of cell surface recognition molecules containing immunoglobulin domains to treat disease
JP2009511453A (en) 2005-10-07 2009-03-19 ファロン ファーマシューティカルズ オサケ ユキチュア Method for treating or preventing ischemic reperfusion injury or multiple organ failure
JP2010184929A (en) 1998-04-28 2010-08-26 Merck Serono Sa POLYOL-IFN-beta CONJUGATE
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
JP2016513253A (en) 2013-02-14 2016-05-12 ファロン ファーマシューティカルズ オサケ ユキチュア Methods for measuring acute respiratory distress syndrome (ARDS) related biomarkers, methods for monitoring the progression and treatment of ARDS in patients
WO2017149199A1 (en) 2016-02-29 2017-09-08 Faron Pharmaceuticals Oy A lyophilised pharmaceutical formulation and its use
US9913880B2 (en) 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0004770B1 (en) * 1978-04-11 1984-06-13 Efamol Limited Pharmaceutical and dietary composition comprising gamma-linolenic acids
CN1369211A (en) * 2001-02-14 2002-09-18 黄伟民 Method for preparing food containing interferon
CN1681527A (en) * 2002-07-17 2005-10-12 比奥根艾迪克Ma公司 Treatment of kidney failure with interferon-beta
CN1579545A (en) * 2003-08-13 2005-02-16 北京金赛狮生物制药技术开发有限公司 Use of regenerated human interferon beta-1b for preparing medicine to prevent and treat SARS
CN103055313A (en) * 2005-07-07 2013-04-24 西特里斯药业公司 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2007124447A2 (en) * 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions
WO2008043570A1 (en) * 2006-10-12 2008-04-17 Helmholtz Zentrum Für Infektionsforschung Interferon type i supporting compounds
WO2012026614A1 (en) * 2010-08-24 2012-03-01 国立大学法人宮崎大学 Composition suppressing matrix-metalloproteinase activity

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03501382A (en) 1987-09-22 1991-03-28 カイロン　コーポレイション Use of recombinant colony stimulating factor-1
JP2010184929A (en) 1998-04-28 2010-08-26 Merck Serono Sa POLYOL-IFN-beta CONJUGATE
US6251598B1 (en) 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
JP2002220343A (en) 2001-01-26 2002-08-09 Toray Ind Inc Life prolongation agent for diffuse lung disease
WO2002074301A1 (en) 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
JP2004531546A (en) 2001-05-16 2004-10-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Use of an IL-18 inhibitor for the treatment or prevention of sepsis
WO2003055916A2 (en) 2001-12-21 2003-07-10 Maxygen Aps Adiponectin fragments and conjugates
JP2007535903A (en) 2003-05-13 2007-12-13 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Activity variants of IL-18 binding protein and their medical applications
JP2008540385A (en) 2005-05-06 2008-11-20 ラボラトワール セローノ ソシエテ アノニム Use of cell surface recognition molecules containing immunoglobulin domains to treat disease
JP2009511453A (en) 2005-10-07 2009-03-19 ファロン ファーマシューティカルズ オサケ ユキチュア Method for treating or preventing ischemic reperfusion injury or multiple organ failure
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
US9913880B2 (en) 2011-02-18 2018-03-13 Stemdr Inc. Method of treating sepsis or septic shock
JP2016513253A (en) 2013-02-14 2016-05-12 ファロン ファーマシューティカルズ オサケ ユキチュア Methods for measuring acute respiratory distress syndrome (ARDS) related biomarkers, methods for monitoring the progression and treatment of ARDS in patients
WO2017149199A1 (en) 2016-02-29 2017-09-08 Faron Pharmaceuticals Oy A lyophilised pharmaceutical formulation and its use

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
Bellingan G., et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir. Med., 2014, 2:98-107. *
Chang et al. "Regulation of lifespan by histone deacetylase," Ageing Research Reviews, Jun. 2002, vol. 1, No. 3, pp. 313-326.
Chen et al. "Increase in Activity During Calorie Restriction Requires Sirt1," Science, Dec. 2005, vol. 310, No. 5754, p. 1641.
Dai et al. "SIRT1 Activation by Small Molecules: Kinetic and Biophysical Evidence for Direct Interaction of Enzyme and Activator," The Journal of Biological Chemistry, Oct. 2010, vol. 285, No. 43, pp. 32695-32703.
Durelli et al. "Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)," Lancet, Apr. 2002, vol. 359, pp. 1453-1460.
Extended Search Report for European Patent Application No. 18174771.8, dated Oct. 4, 2018, 8 pages.
International Search Report for PCT/KR2012/001225 dated Sep. 12, 2012 from Korean Intellectual Property Office.
Kiss, J., et al. IFN-beta protects from vascular leakage via up-regulation of CD73. Eur. J. Immunol., 2007, 37:3334-3338. *
Kokkinakis et al. "Modulation of Gene Expression in Human Central Nervous System Tumors under Methionine Deprivation-induced Stress," Cancer Research, Oct. 2004, vol. 64, pp. 7513-7525.
Kwon et al. "The ups and downs of SIRT1," Trends in Biochemical Sciences, Nov. 2008, vol. 33, No. 11, pp. 517-525.
Li et al. "Dual role of leukotriene B4 receptor type 1 in experimental sepsis," Journal of Surgical Research, 2015, vol. 193, pp. 902-908.
Liu et al. "NAD+-dependent SIRT1 Deacetylase Participates in Epigenetic Reprogramming during Endotoxin Tolerance," The Journal of Biological Chemistry, Mar. 2011, vol. 286, No. 11, pp. 9856-9864.
Matsukawa et al. "Endogenous Monocyte Chemoattractant Protein-1 (MCP-1) Protects Mice in a Model of Acute Septic Peritonitis: Cross-Talk Between MCP-1 and Leukotriene B4," J. Immunol., 1999, vol. 163, No. 11, pp. 6148-6154.
Milne et al. "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes," Nature, Nov. 2007, vol. 450, No. 7170, pp. 712-716.
Nemzek et al. "Modeling Sepsis in the Laboratory: Merging Sound Science with Animal Well-Being," Comparative Medicine, Apr. 2008, vol. 58, No. 2, pp. 120-128.
Notice of Allowance for U.S. Appl. No. 13/818,847, dated Nov. 24, 2017 7 pages.
Official Action for Japan Patent Application No. 2016-219996, dated Aug. 9, 2017, 3 pages.
Official Action for U.S. Appl. No. 13/818,847, dated Aug. 22, 2013 7 pages Restriction Requirement.
Official Action for U.S. Appl. No. 13/818,847, dated Dec. 13, 2016 11 pages.
Official Action for U.S. Appl. No. 13/818,847, dated Feb. 27, 2014 9 pages.
Official Action for U.S. Appl. No. 13/818,847, dated Jan. 28, 2016 11 pages.
Official Action for U.S. Appl. No. 13/818,847, dated Jul. 27, 2017 6 pages.
Official Action for U.S. Appl. No. 13/818,847, dated Oct. 20, 2014 9 pages.
Official Action with English Translation for Japan Patent Application No. 2018-159014, dated Jan. 7, 2020, 5 pages.
Official Action with English Translation for Japan Patent Application No. 2018-159014, dated Jul. 2, 2019, 6 pages.
Sharma, S. Acute respiratory distress syndrome. BMJ Clinical Evidence, 2010, 11:1511, p. 1-18. *
Sharma, S. Acute respiratory distress syndrome. Clinical Evidence, 2010, 11:1511, p. 1-18. *
Vaziri et al. "hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase," Cell, Oct. 2001, vol. 107, No. 2, pp. 149-159.
Weighardt et al. "Type I IFN Modulates Host Defense and Late Hyperinflammation in Septic Peritonitis," The Journal of Immunology, 2006, vol. 177, pp. 5623-5630.
Yoo, C-H., et al. Interferon beta protects against lethal endotoxic and septic shock through SIRT1 upregulation. Scientific Reports, 2014, 4:4220, p. 1-8. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260005230A (en) 2023-04-21 2026-01-09 이데미쓰 고산 가부시키가이샤 Compounds, materials for organic electroluminescent devices, organic electroluminescent devices and electronic devices

Also Published As

Publication number Publication date
JP2018203758A (en) 2018-12-27
EP3395356B1 (en) 2021-05-19
WO2012112007A3 (en) 2012-10-26
US20130150555A1 (en) 2013-06-13
JP2014506889A (en) 2014-03-20
JP2017081922A (en) 2017-05-18
EP2676675B1 (en) 2019-04-10
EP3395356A1 (en) 2018-10-31
JP6697041B2 (en) 2020-05-20
KR101451357B1 (en) 2014-10-15
EP2676675A2 (en) 2013-12-25
CN103228290A (en) 2013-07-31
US20180161398A1 (en) 2018-06-14
JP6441290B2 (en) 2018-12-19
KR20120095324A (en) 2012-08-28
WO2012112007A2 (en) 2012-08-23
US9913880B2 (en) 2018-03-13
EP2676675A4 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
US11413333B2 (en) Composition containing inducer of SIRT1 expression for preventing or treating sepsis or septic shock
KR102204299B1 (en) Therapeutic agent for coronavirus comprising Elaeocarpus sylvestris extract as effective component
US20130178430A1 (en) Compositions for Prevention or Treatment of Hepatitis C Virus Containing ginsenoside Rg3 as an Active Ingredient
CN107580496A (en) The anti-glycosuria effect of gypenoside 75
KR20240015980A (en) A composition for preventing, improving and treating of diabetes comprising extract of pepper leaves and extract of Helianthus tuberosus as effective component
KR101731252B1 (en) Peptide having anti-diabetic activity and use thereof
KR102203626B1 (en) Pharmaceutical and functional food composition comprising phosvitin and lysozyme for enhancing immunity
KR101534498B1 (en) Composition comprising the extract of Ceramium boydenii for preventing and treating inflammatory diseases
KR101843996B1 (en) A composition for improving, preventing and treating pulmonary disease comprising Lycium Chinese fruit extract and Kaempferia parviflora extract
KR102326439B1 (en) Antimicrobial, anti-inflammatory, antiviral and immunologically enhancing composition comprising ginseng
KR102014344B1 (en) Pharmaceutical composition comprising cystatin A and cystatin D for treating colorectal disease
RU2780346C1 (en) Therapeutic agent against coronavirus including an elaeocarpus sylvestris extract
KR102364723B1 (en) Composition for modulating immunity comprising myeloid-derived suppressor cells and regulatory T cell
KR20240115620A (en) Composition for Preventing and Treating Gout Comprising B. vulgatus as an effective ingredient
KR20250122550A (en) A composition for improving, preventing and treating of hypertension comprising mushroom extract
KR20250014580A (en) Composition for preventing, ameliorating or treating vascular diseases comprising Diospyros lotus leaf extract as effective component
KR101894657B1 (en) A composition comprising mixture of the extract of Broadleaf Liriope and silkworm powder for improving immunity
KR101074521B1 (en) Natural calcium compound of hypoglycemic effect
KR20180006535A (en) Composition for preventing or treating diabetes comprising extracts of Corni fructus
KR20180000124A (en) Composition for improving metabolism containing extraction of Cinnamomum cassia Blume
KR20240025252A (en) Pharmaceutical composition for prevention or treatment of epilepsy included west&#39;s syndrome
KR20230161337A (en) Composition for prevention, improvement or treatment of arthritis comprising Lysimachia japonica extract as effective component
JP5097935B2 (en) Composition for suppressing and / or preventing abnormal production of cytokines in mammals
KR20190021077A (en) Compositions for preventing or treating diabetes
KR20220169024A (en) Composition for enhancing pulmonary function having extract of Rehmannia glutinosa Liboschitz var

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: STEMDR INC., KOREA, REPUBLIC OF

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAN, MYUNG KWAN;YOO, CHAE HWA;SONG, EUN KYUNG;AND OTHERS;REEL/FRAME:045717/0266

Effective date: 20180501

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE